We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 87.70 | 100.00 | 85.25 | 0.00 | 07:00:05 |
From Apr 2019 to Apr 2024
By Giulia Petroni
Sanofi SA said late Wednesday that the U.S. Food and Drug Administration has approved Sarclisa, or isatuximab, in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
The French pharmaceutical company said the treatment is for adult patients with RRMM who have already received one to three prior therapies.
According to the Phase 3 Ikema study, the Sarclisa combination treatment allows for the reduction of risk of disease progression or death by 45%, Sanofi said.
The FDA had previously approved the Sarclisa regimen for the treatment of adults with RRMM who have received at least two prior therapies.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
April 01, 2021 01:22 ET (05:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
